MDMA

1. 2026-10-19issueIssued info_card
2. 2026-10-02srcPotential Psychiatric Uses for MDMA
3. 2026-10-02srcSerotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4-methylenedioxymethamphetamine users
4. 2026-10-02srcMDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials
5. 2026-10-02srcReduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study
6. 2026-10-02srcMDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials [RETRACTED]
7. 2026-10-02srcMDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward
8. 2026-10-02srcSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
9. 2026-10-02srcMDMA impairs cognitive function during withdrawal via activation of the arachidonic acid cascade in the hippocampus
10. 2026-10-02srcEfficacy of MDMA-assisted therapy for PTSD: A systematic review and meta-analysis
11. 2026-10-02srcAdverse events associated with classic psychedelics and MDMA: a real-world population-based study using WHO pharmacovigilance database (VigiBase)
12. 2026-10-02srcPlasma oxytocin concentrations following MDMA or intranasal oxytocin in humans
13. 2026-10-02srcMeta-analysis of executive functioning in ecstasy/polydrug users
14. 2026-10-02srcPharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination
15. 2026-10-02srcEffects of MDMA and Intranasal oxytocin on social and emotional processing
16. 2026-10-02srcMDMA Impairs Both the Encoding and Retrieval of Emotional Recollections
17. 2026-10-02srcEffects of MDMA on attention to positive social cues and pleasantness of affective touch
18. 2026-10-02srcAcute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants
19. 2026-10-02srcMDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
20. 2026-10-02srcMDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
21. 2026-10-02srcMemory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities
22. 2026-10-02srcRediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin
23. 2026-10-02srcResidual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs
24. 2026-10-02srcAmphetamine, MDMA, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
25. 2026-10-02srcThe pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")
26. 2026-10-02srcThe safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
27. 2026-10-02srcA randomized, controlled pilot study of MDMA-assisted psychotherapy for treatment of resistant, chronic PTSD
28. 2026-10-02srcAcute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment
29. 2026-10-02srcCharacterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time
30. 2026-10-02srcHallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
31. 2026-10-02srcSex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans
32. 2026-10-02srcThe harmful health effects of recreational ecstasy: a systematic review of observational evidence
33. 2026-10-02srcIntracranial Pressure-Guided Therapy in MDMA-Induced Cerebral Edema: A Case Report
34. 2026-10-02srcHuman pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects
35. 2026-10-02srcThe serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of MDMA ('Ecstasy') in healthy volunteers
36. 2026-10-02srcAcute liver failure following the use of ecstasy (MDMA)
37. 2026-10-02srcWhich neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies
38. 2026-10-02srcThe 'ecstasy' hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine
39. 2026-10-02srcStudy of the behavioural responses related to the potential addictive properties of MDMA in mice
40. 2026-10-02srcHuman pharmacology of MDMA: pharmacokinetics, metabolism, and disposition
41. 2026-10-02srcPharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters
42. 2026-10-02srcContribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe
43. 2026-10-02srcMDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress
44. 2026-10-02src3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings
45. 2026-10-02srcThe origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents
46. 2026-10-02srcThe origin of MDMA ("ecstasy")--separating the facts from the myth
47. 2026-10-02srcMethylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity
48. 2026-10-02srcMDMA scheduling history and DEA Schedule I placement
49. 2026-10-02srcAustralia TGA rescheduling MDMA to Schedule 8 for PTSD treatment
50. 2026-09-27runbrief run
51. 2026-09-27revisionr1.a1
52. 2026-09-04issueIssued emergency
53. 2026-09-04issueIssued info_card
54. 2026-09-04issueIssued notice
55. 2026-07-03proposaldependence · taper
56. 2026-06-04proposal33 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
57. 2026-06-04publicationPublication — backfill
58. 2026-04-20proposalduration · oral · aftereffects
59. 2026-04-20proposalduration · oral · total
60. 2026-04-20proposalduration · oral · offset
61. 2026-04-20proposalduration · oral · peak
62. 2026-04-20proposalduration · oral · come_up
63. 2026-04-20proposalduration · oral · onset
64. 2026-04-20proposaldosage · oral
65. 2026-04-20proposaltolerance
66. 2026-04-20proposalwithdrawal
67. 2026-04-20proposaldependence · full
68. 2026-04-20proposaltoxicity
69. 2026-04-20proposaltimeline · oral · afterglow
70. 2026-04-20proposaltimeline · oral · resolution
71. 2026-04-20proposaltimeline · oral · plateau
72. 2026-04-20proposaltimeline · oral · peak
73. 2026-04-20proposaltimeline · oral · come_up
74. 2026-04-20proposaltimeline · oral · onset
75. 2026-04-20proposaldose_tier · heavy
76. 2026-04-20proposaldose_tier · strong
77. 2026-04-20proposaldose_tier · common
78. 2026-04-20proposaldose_tier · light
79. 2026-04-20proposaldose_tier · threshold
80. 2026-04-20revisionRevision 1
81. 2026-04-20genGeneration — pipeline-v5pipeline-v5
82. 2026-04-20rungeneration run
83. 2026-04-20rungeneration run

The same entries, as forms: six forms.